Altacor’s current portfolio comprises of three product categories,
Dry Eye Prescription Products
Clinitas Gel Rx
Clinitas Gel is a liquid gel for the treatment of Dry Eye. It contains carbomer 980, a synthetic polymer and is formulated to produce a transparent, lubricating film covering the cornea and conjunctiva.
Clinitas & Clinitas Multi Rx
Clinitas Rx is a preservative-free eye drop that contains sodium hyaluronate 0.4%, an ophthalmic lubricant, for the relief of DES. This popular product is now available in both unit dose and multi dose formats.
Dry Eye Retail Products
This range also comprises three products which together cover mild, moderate and severe Dry Eye and are recommended by pharmacists and opticians.
This is the sister product to Clinitas Gel and is used in an identical manner when recommended by optical professionals and sold over the counter.
Clinitas Soothe and Clinitas Soothe Multi
Clinitas Soothe and Clinitas Soothe Multi are retail versions of Clinitas Rx. It is stocked in a number of leading pharmacies (e.g. Boots) and optical chains (e.g. Vision Express, Specsavers) and is designed to be used by patients who have moderate Dry Eye.
Blepharitis is an irritation of the eyelid margin which may have inflammatory elements and is allied to Dry Eye. It is associated with meibomian gland dysfunction and treatment is focussed towards restoring meibomian functionality. Altacor’s products, when used together, are an effective means of achieving this.
BlephaMask is a reusable eye mask containing a temperature tester to ensure optimum working temperature for safety and efficacy. Applied to the closed eye for 10 minutes, BlephaMask liquefies and loosens meibomian secretions.
BlephaCura is used to remove meibomian secretions loosened by BlephaMask and as a daily eyelid cleaner to promote eyelid hygiene and health. BlephaCura encourages and promotes the natural healing process in response to inflammation and irritation of the eyelids.
BioLon - 1% sodium hyaluronate viscoelastic
Altacor is pleased to announce that from 1st April 2016 it is assuming the exclusive responsibility from Kestrel Ophthalmics for the marketing of BioLon®, a viscoelastic for use in cataract and other ophthalmic surgery.
BioLon® contains highly engineered, ultrapure hyaluronic acid (1%) with optimised viscosity in an easy to use 1ml syringe which is designed to be bubble free. BioLon® can be reliably used wherever anterior chamber depth maintenance is important. It protects endothelial cells and is easy to remove after the procedure is complete due to its cohesive nature.
BioLon® is the first product in Altacor’s new ophthalmic surgical portfolio which will be expanded with further complimentary products.
BioLon® will continue to be available direct from Alloga or AAH. Please contact your Altacor Representative for further information or call Altacor on 01223 421411 and we will be pleased to assist you.
Comfortear Lacrisolve 180 Absorbable Punctum Plugs
From the 1st of April 2017 Altacor has added to its portfolio of dry eye products with the addition of some new punctal plugs.
LacrisolveTM plugs provide predictable occlusion therapy lasting up to 180 days, almost double the duration of most other absorbable plugs. The new plugs are intended to temporarily treat the symptoms of dry eye disease (including postsurgery), contact lens intolerance secondary to dry eye, and to increase efficacy of ocular medications and lubricants.
Made from an innovative polymer material called polydioxanone, the plugs are designed with precision and made for comfort.
They are available in two sizes: 0.4mm and 0.5mm. The implants are supplied sterile with two plugs provided per pack.
Aimed at both specialist opticians with an interest in dry eye and consultant ophthalmologists in hospitals, Comfortear Lacrisolve 180 Plugs are an ideal addition to a healthcare professionals tool kit for when patients need more than drops to treat dry eye.
Amniotic membrane-derived dry biological matrix
NuVision Biotherapies Limited, a regenerative wound treatment company, and Altacor, a leading ophthalmic specialist, have announced the signing of a strategic partnership to distribute the sight saving therapy, Omnigen, throughout England, Scotland and Wales.
Through this agreement, Altacor will act as the exclusive distributor for the Omnigen product range to healthcare customers, with NuVision providing expert technical, scientific and clinical support. This unique offering of strong UK-based pharma and regenerative medicine is a milestone for ocular surface medicine, and for the future development and dissemination of personalised regenerative therapies.
Omnigen is a ground-breaking, patented, dry preparation of human-derived amniotic membrane, made from the sac surrounding the baby during pregnancy. The Tereo® manufacturing process transforms this waste product of birth into a sterile and stable dry regenerative therapy that can be easily shipped and accessed anywhere in the world. Omnigen is applied directly to the wound dry and is rapidly and effectively rehydrated using surrounding moisture to immediately reactivate the beneficial properties to promote tissue repair and healing in a variety of ways. The product represents a unique and versatile "off-the-shelf" regenerative product that can be manufactured in a scalable manner, may be stored long term, and is administered without tissue matching or the need for immune suppression. The Tereo process improves the wound healing action and provides surgeons with an effective sight saving therapy that could provide a meaningful benefit to patients, including those suffering from serious sight destroying ocular surface diseases and conditions with unmet medical need.